Exome sequencing in tracking clonal evolution in multiple myeloma following therapy

Sequencing the tumor genome using next-generation sequencing (NGS) is providing an unparalleled insight into the pathogenesis and progression of the disease. Much of the current focus of NGS in cancer is on defining mutations in the tumor genome at disease presentation, and these findings are central to understanding the molecular mechanisms that underlie pathogenesis.